VM:CC - Voyageur Pharmaceuticals Ltd. Announces Closing of Private Placement

(TheNewswire)

Calgary, Canada / TheNewswire/ March 1, 2024 - Voyageur Pharmaceuticals Ltd . ( TSX.V:VM ) (USA:VYYRF) ("Voyageur" orthe "Company"), a provider of innovative medical imagingsolutions, is pleased to announce it has closed its previouslyannounced (January 16, 2024) non-brokered private placement (the"Offering") of units ("Units") sold at a price of$0.08 per Unit.  Pursuant to the Offering, the Company issued6,106,250 Units for total gross proceeds of $488,500.

Each Unit is comprised of one common share in thecapital of the Company (each, a "Common Share") and oneCommon Share purchase warrant (each, a "Warrant"), with eachWarrant exercisable at $0.15 for twenty-four months fromclosing.

In connection with the Offering, Voyageur paid cashcommissions to qualified non-related parties of $10,440 and issued anaggregate of 130,500 broker warrants (the "BrokerWarrants"). Each Broker Warrant entitles the holder to acquireone Common Share at a price of $0.08 per Broker Warrant for a periodof one (1) year from the date of issuance.

The Company expects to use the gross proceeds from theOffering, net of the cash commissions described above asfollows:

Marketing and sales launch                      $160,000

Product testing                                     $60,000

Audit and listing / TSXV fees                $60,000

Corporate G&A (incl. Offering costs)         $198,000

Total                                                            $478,000

The Common Shares, Warrants and Broker Warrants issuedpursuant to the Offering are subject to a four month hold period fromthe date of issuance.

About Voyageur PharmaceuticalsLtd.

Voyageur, a Canadian public company trading under thesymbol VM on the TSX Venture Exchange, is in development of barium,iodine and carbon Active Pharmaceutical Ingredients (API) andhigh-performance, cost-effective imaging contrast agents. With astrategic focus on vertically integrating the barium, iodine andcarbon contrast imaging market, Voyageur aims to become a key playerby producing its own barium, iodine, and fullerene minerals.

Voyageur's business plan is set to generate cash flowby partnering with established third-party GMP pharmaceuticalmanufacturers in Canada, ensuring the validation of its products byregulatory agencies worldwide. As the Company solidifies its presencein the market, it will transition into a high-margin domesticmanufacturer of radiology drugs, further expanding its revenuestreams.

Voyageur is committed to sustainability andenvironmental stewardship. The Company envisions a future where carbonneutrality is the norm, and to achieve this, it plans to buildstate-of-the-art carbon-neutral infrastructure. By investing in carbonneutral energy sources and sustainable manufacturing practices, itaims to become 100% self-sufficient across all its manufacturingactivities. Voyageur's commitment to the environment sets it apart asa pioneer in the industry.

At the core of the Company's operations, Voyageur ownsa 100% interest in the Frances Creek property, a barium sulphate(barite) project. Additionally, Voyageur holds interests in ahigh-grade iodine, lithium, and bromine brine project situated inUtah, USA, further bolstering its position in the industry. Voyageuralso owns a 100% interest in two battery mineral properties whichfocus on copper/zinc development.

Voyageur's ambitious vision is to become the firstvertically integrated, carbon-neutral company in the imaging contrastmedia drug market. By controlling all primary input costs, from thesourcing of raw materials to final production, it plans to ensureunmatched quality and cost efficiency. Voyageur embodies the motto of" From the Earth to theBottle ," highlighting its commitment toresponsible sourcing and manufacturing practices.

For Further Information:

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.

NOT FOR DISSEMINATION IN THE UNITEDSTATES

Cautionary Statement Regarding “Forward-Looking”Information

This news release may contain certainforward-looking information and statements, including withoutlimitation, statements pertaining to the use of proceeds from theOffering, statements with respect to the Company's business plan andthe Company's expectation of becoming a high margin domesticmanufacturer of radiology drugs, and Voyageur's plans to become selfsufficient and vertically integrated, and other statements herein,which expressly or impliedly speak to Voyageur's expectations for itsbusiness and operations. All statements included herein, other thanstatements of historical fact, are forward-looking information andsuch information involves various risks and uncertainties, including,without limitation, capital market risks and uncertainty, globalmarket factors and supply chain issues, risks relating to theregulation and approval of Voyageur's products, and general risksrelating to Voyageur's business. There can be no assurance that suchinformation will prove to be accurate, and actual results and futureevents could differ materially from those anticipated in suchinformation. A description of assumptions used to develop suchforward-looking information and a description of risk factors that maycause actual results to differ materially from forward-lookinginformation can be found in the Company's disclosure documents on theSEDAR+ website at www.sedarplus.ca. Voyageur does not undertake toupdate any forward-looking information except in accordance withapplicable securities laws.

Copyright (c) 2024 TheNewswire - All rights reserved.